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BACKGROUND & AIMS: Patients chronically infected with the
hepatitis B virus rarely achieve loss of serum hepatitis B sur-
face antigen (HBsAg) with the standard of care. We evaluated
HBsAg loss in patients receiving the combination of tenofovir
disoproxil fumarate (TDF) and peginterferon a-2a (peginter-
feron) for a ﬁnite duration in a randomized trial. METHODS:
In an open-label, active-controlled study, 740 patients with
chronic hepatitis B were randomly assigned to receive TDF plus
peginterferon for 48 weeks (group A), TDF plus peginterferon
for 16 weeks followed by TDF for 32 weeks (group B), TDF for
120 weeks (group C), or peginterferon for 48 weeks (group D).
The primary end point was the proportion of patients with
serum HBsAg loss at week 72. RESULTS: At week seventy-two,
9.1% of subjects in group A had HBsAg loss compared with
2.8% of subjects in group B, none of the subjects in group C,
and 2.8% of subjects in group D. A signiﬁcantly higher pro-
portion of subjects in group A had HBsAg loss than in group C
(P < .001) or group D (P ¼ .003). However, the proportions of
subjects with HBsAg loss did not differ signiﬁcantly between
group B and group C (P ¼ .466) or group D (P ¼ .883). HBsAg
loss in group A occurred in hepatitis B e antigenpositive and
hepatitis B e antigennegative patients with all major viral
genotypes. The incidence of common adverse events (includingheadache, alopecia, and pyrexia) and treatment discontin-
uation due to adverse events was similar among groups.
CONCLUSIONS: A signiﬁcantly greater proportion of patients
receiving TDF plus peginterferon for 48 weeks had HBsAg loss
than those receiving TDF or peginterferon alone. ClinicalTrials.
gov ID NCT01277601.Keywords: HBV; HBeAg Seroconversion; Virologic Response;
Clinical Trial.
p to 400 million people worldwide are chronically
1Uinfected with hepatitis B virus (HBV). Almost all
newly infected adults are able to clear the virus without
therapy, but 80%90% of infants infected during the ﬁrst
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Ryear of life and 30%50% of children infected by the age of
6 years develop chronic HBV infection.2 Chronic infection is
linked to the persistence of covalently closed circular HBV
DNA within the nucleus of hepatocytes.2 The presence of
hepatitis B surface antigen (HBsAg) in the serum is a sur-
rogate marker for covalently closed circular HBV DNA
transcriptional activity.2–5 Clearance of HBsAg from the
serum is associated with a functional remission of chronic
hepatitis B (CHB) and improved long-term outcomes.6,7
HBsAg loss is therefore recognized as the optimal thera-
peutic goal.1,8,9
Standard treatment of patients with CHB involves either a
ﬁnite course of pegylated interferon-a (peginterferon), which
stimulates the natural immune response against the virus,10
or an oral antiviral for an indeﬁnite duration, which sup-
presses replication of HBV to undetectable levels.1,8,9 How-
ever, HBsAg loss is uncommon with both treatment
strategies. In the trials of peginterferon a-2a given for 48
weeks, only 4%of hepatitis B e antigen (HBeAg)-negative and
4% of HBeAg-positive had HBsAg loss 6 months after the end
of treatment.11,12 In the phase 3 trials of tenofovir disoproxil
fumarate (TDF), the rate of HBsAg loss was only 3% in
HBeAg-positive patients who received 48weeks of treatment
with TDF, and no HBeAg-negative patients lost HBsAg.13
As peginterferon and antivirals have different mecha-
nisms of action, it has been hypothesized that combining
the 2 drug classes could improve rates of HBsAg loss.
Several trials have evaluated combination treatment with
peginterferon and oral antivirals for patients with CHB, but
the results are inconclusive.11,12,14–18 None of these trials
were designed to evaluate serum HBsAg loss as a primary
end point. We, therefore, compared the efﬁcacy and safety
of TDF (a potent oral nucleotide antiviral with a high
barrier to resistance) and peginterferon combination
therapy with TDF and peginterferon alone in patients with
CHB. We also included a combination regimen involving a
short duration (16 weeks) of peginterferon to explore
whether a peginterferon-sparing regimen affected rates of
HBsAg loss.Methods
Study Design
This was a randomized, open-label, active-controlled,
multinational, superiority trial (ClinicalTrials.gov ID
NCT01277601). Patients received TDF (300 mg once daily
orally) and peginterferon a-2a (180 mg/week, subcutaneously)
separately or concomitantly. Patients were randomly assigned
1:1:1:1 to 1 of 4 treatment groups: TDF plus peginterferon for
48 weeks (group A); TDF plus peginterferon for 16 weeks
followed by 32 weeks of TDF alone (group B); TDF alone for
120 weeks (group C); or peginterferon alone for 48 weeks
(group D). All groups were followed to week 120. The protocol
is provided in the Supplementary Material. All authors had
access to the data, assume responsibility for the integrity and
completeness of the reported data, and approved the manu-
script for submission.
During follow-up, any patient who developed either hepatic
decompensation or virologic or biochemical relapse(Supplementary Material) was retreated with TDF mono-
therapy (300 mg once daily orally).
The study was approved by the Institutional Review Board
or Independent Ethics Committee at each site and was con-
ducted according to the Declaration of Helsinki, Good Clinical
Practice guidelines, and local regulatory requirements. The
investigators, participating institutions, and sponsor agreed to
maintain conﬁdentiality of the data.
Randomization was done centrally through an Interactive
Voice Response System. The randomization sequence was
generated by an independent company using a computer pro-
gram. Randomization was stratiﬁed by screening HBeAg status
and HBV genotype to form 10 strata (Supplementary Table 1).
Patients
Patients aged 1875 years with CHB were enrolled at 139
sites in 19 countries (Australia, Canada, France, Germany,
Greece, Hong Kong, India, Italy, The Netherlands, Poland,
Portugal, Romania, Singapore, South Korea, Spain, Taiwan,
Turkey, United Kingdom, and United States) from March 2011
to March 2013. Eligible patients were HBeAg-positive or
HBeAg-negative and had not previously received treatment
with interferon or nucleotide analogs. Patients who had
received nucleoside analogs were eligible provided that they
received the ﬁnal dose at least 24 weeks before screening.
HBeAg-positive patients were required to have HBV DNA levels
20,000 IU/mL and HBeAg-negative patients 2000 IU/mL.
Men were required to have alanine aminotransferase (ALT)
levels >54 U/L and 400 U/L, and women >36 U/L and 300
U/L. Patients with bridging ﬁbrosis or cirrhosis documented
within the previous 12 months were excluded to reduce the
risk of liver decompensation associated with ALT ﬂares. Full
eligibility criteria are provided in the Supplementary Material.
All patients signed an informed consent form before screening
in accordance with regulatory and local ethics committee
requirements.
Study Assessments
Study visit assessments included measurement of serum
HBsAg (Architect assay; Abbott Diagnostics, lower limit of
detection: 0.05 IU/mL) and serum HBV DNA (polymerase chain
reaction-based m2000sp/m2000rt; Abbott Diagnostics, lower
limit of quantiﬁcation: 15 IU/mL) in addition to standard lab-
oratory, clinical, and safety assessments as described in
Supplementary Table 2. The primary end point, HBsAg loss,
was determined using the Architect Qualitative II assay (Abbott
Diagnostics, lower limit of detection 1 S/CO).
Viral resistance testing (Supplementary Material) was con-
ducted in patients with HBV DNA 117 IU/mL at weeks 48 or
72 who had received at least 24 weeks of TDF.
All speciﬁed laboratory tests were performed at a central
laboratory.
Outcomes
The primary efﬁcacy end point was the proportion of pa-
tients with HBsAg loss at week 72 by KaplanMeier analysis:
the primary hypothesis compared group A with groups C or D;
the secondary hypothesis compared group B with groups C or
D. Secondary end points at weeks 48 and 72 included anti-HBs
seroconversion, HBeAg loss, anti-HBe seroconversion, HBsAg
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mL) and normalization of ALT. Sustained response (deﬁned as
HBV DNA <2000 IU/mL and normalization of ALT) was also
assessed at week 72. Other endpoints included retreatment
with TDF during the follow-up period and overall safety.Statistical Analysis
All patients who received at least one dose of study drug
were included in the efﬁcacy and safety analyses. In order to
characterize the full safety proﬁle within this study, all avail-
able data up to and beyond week 72 were included in the safety
analysis.
In the primary analysis, the proportion of patients with
HBsAg loss at week 72 was estimated by a KaplanMeier
method. A predeﬁned 2-state Markov analysis was also con-
ducted to account for HBsAg seroreversion as this serologic
aspect is not reﬂected in the KaplanMeier analysis. Details of
the 2-state Markov analysis has been published previously.13
Brieﬂy, the Markov model allows transitions between
response (HBsAg loss) and nonresponse (HBsAg seroreversion)
during the time of interest, whereas the KaplanMeier method
only allows the transition from nonresponse to response and
ignores the transition from response to nonresponse. Data for
patients without HBsAg loss were censored at the last time-
point observed. Comparisons between groups were conducted
via stratiﬁed log-rank tests, by baseline HBeAg status and HBV
genotype.
For the primary efﬁcacy end point, multiplicity adjustments
using a multistage gatekeeping approach19 controlled the study-
wise error rate at <.05. Movement from primary hypothesis to
the secondary hypothesis is predicated on rejection of at least
one null hypothesis in the primary hypothesis. For all other
comparisons, unadjusted P values are presented. Overall, 180
patients per treatment group would provide the study with
about 80% power to detect a 10% difference in HBsAg loss,
assuming that the test group (either group A or group B) had an
HBsAg loss rate of 13% and the control arm had an HBsAg loss
rate of 3% for both the primary and secondary hypotheses. The
power/sample size calculation was based on a 2-sided type I
error rate of .025. The sample size was calculated based on a
complementary loglog transformation of the ﬁxed-point sur-
vival test. It was also conﬁrmed using Fisher’s exact test.
Associations between baseline and on-treatment variables
with HBsAg loss during the 72-week period were examined via
a post-hoc exploratory Cox regression analysis. Additional sta-
tistical details are provided in the protocol (Supplementary
Material).Results
Of the 1597 patients screened, 751 were randomized
and 740 received treatment (Supplementary Figure 1;
Supplementary Table 3). Most patients were male (66%),
Asian (75%), HBeAg-positive (58%), and 42% had HBV
genotype C (Table 1). The demographics and baseline clin-
ical characteristics of the patients were balanced across the
4 treatment groups (Table 1).
At week 72, the KaplanMeier cumulative estimate of
HBsAg loss was 9.1% for group A, 2.8% for group B, 0% for
group C, and 2.8% for group D. The rate of HBsAg loss ingroup A was signiﬁcantly higher than rates for groups C
(P < .001) or D (P ¼ .003), establishing superiority in
achieving HBsAg loss for the combination regimen over
monotherapy with either TDF or peginterferon (Figure 1;
Table 2). HBsAg loss in group A occurred in both HBeAg-
positive and HBeAg-negative patients and across all major
viral genotypes, with the highest rate occurring in genotype
A patients (Table 3; Supplementary Tables 4 and 5). The
rate of HBsAg loss in group B did not signiﬁcantly differ
from that of groups C (P ¼ .466) or group D (P ¼ .883)
(Table 2). A post-hoc exploratory comparison demonstrated
a signiﬁcantly higher rate of HBsAg loss in group A than in
group B (unadjusted P ¼ .002).
Between weeks 48 and 72, seven patients who had
HBsAg loss on at least one study visit experienced HBsAg
seroreversion (5 HBeAg-positive patients: 3 in group A
[2 genotype A patients and 1 genotype B patient], 2 in group
B [genotype A], and 2 HBeAg-negative patients: 1 in group A
and 1 in group B [both genotype B]). Of these, 5 had ach-
ieved HBsAg loss at or after end of treatment at week 48. To
assess the impact of HBsAg seroreversion on overall efﬁ-
cacy, we conducted a 2-state Markov model analysis that
revealed statistical signiﬁcance in the comparison between
groups A and C, but not between groups A and D (Table 2).
The multivariable Cox regression analysis identiﬁed 2
baseline factors that were independently associated with
HBsAg loss: HBV genotype A and assignment to treatment
group A (TDF plus peginterferon for 48 weeks). Two
on-treatment factors were found to be strongly associated
with HBsAg loss: increase in ALT to >400 U/L (males) or
>300 U/L (females) during the ﬁrst 12 weeks of therapy
and having >1 log10 decline in HBsAg from baseline to week
12 (Supplementary Tables 6 and 7).
The rate in group A was signiﬁcantly higher than the
rates for groups C (P < .001) and D (P ¼ .005) (Table 2).
The rate of anti-HBs seroconversion at week 72 for group B
did not differ signiﬁcantly from that of groups C (P ¼ .800)
or D (P ¼ .177). A post-hoc exploratory comparison
demonstrated a signiﬁcantly higher rate of anti-HBs sero-
conversion in group A than in group B (unadjusted P <
.001). Of the 17 patients who maintained HBsAg loss at
week 72 with any treatment regimen, 15 (88%) achieved
anti-HBs seroconversion.
Mean HBsAg decline from baseline to week 48 was
signiﬁcantly greater in group A (1.1 log10 IU/mL) than in
groups B, C, and D (0.5, 0.3 and 0.8 log10 IU/mL, respec-
tively, P < .05 for all comparisons vs group A) (Figure 2).
Patients in group B who received only 16 weeks of pegin-
terferon had smaller declines of HBsAg between weeks 16
and 48 than did patients in group A, who received 48 weeks
of peginterferon. At week 72, in patients who had not been
retreated with TDF, group A demonstrated signiﬁcantly
greater HBsAg decline compared with all other groups (1.3
vs 0.3, 0.4, 0.6 log10 IU/mL , respectively, P < .05 for all
comparisons vs group A).
At week 48, rates of HBeAg loss and anti-HBe serocon-
version were higher in group A than in groups C and D
(P < .05); at week 72, rates of HBeAg loss and anti-HBe
seroconversion in group A were only higher than group C
Table 1.Demographic and Clinical Characteristics of the Patients at Baseline
Characteristics
Group A (n ¼ 186)
TDF þ peginterferon
for 48 wk
Group B (n ¼ 184)
TDF þ peginterferon
for 16 weeks, then
TDF for 32 wk
Group C (n ¼ 185)
TDF for 120 wk
Group D (n ¼ 185)
peginterferon for
48 wk
Age, y, mean ± SD (range) 38 ± 16.7 (1869) 37 ± 9. (1862) 36 ± 10.9 (1866) 38 ± 10.5 (1864)
Body mass index
Mean ± SD 24 ± 3.4 24 ± 4.0 25 ± 4.1 24 ± 4.0
Range 17–37 17–46 17–45 16–45
Male sex, n (%) 127 (68) 119 (65) 121 (65) 119 (64)
Race, n (%)
Asian 142 (76) 134 (73) 141 (76) 137 (74)
Blacka 5 (3) 3 (2) 4 (2) 6 (3)
White 36 (19) 45 (25) 39 (21) 41 (22)
Other 3 (2) 2 (1) 1 (1) 1 (1)
Region, n (%)
North America 38 (20) 31 (17) 37 (20) 37 (20)
Europe 42 (23) 52 (28) 40 (22) 45 (24)
Australia/New Zealand 10 (5) 14 (8) 15 (8) 14 (8)
Asia 96 (52) 87 (47) 93 (50) 89 (48)
HBV genotype,b n (%)
A 17 (9) 16 (9) 14 (8) 14 (8)
B 50 (27) 51 (28) 49 (27) 53 (29)
C 78 (42) 79 (43) 78 (42) 79 (43)
D 39 (21) 36 (20) 41 (22) 38 (21)
EH 2 (1) 2 (1) 3 (2) 1 (1)
HBeAg-positive, n (%) 108 (58) 105 (57) 109 (59) 106 (57)
HBV DNA, log10 IU/mL, mean ± SD 7.1 ± 1.5 7.1 ± 1.5 7.0 ± 1.5 6.9 ± 1.6
HBsAg, log10 IU/mL, mean ± SD 3.9 ± 0.8 3.8 ± 0.9 3.9 ± 0.8 3.8 ± 0.8
ALT, U/L, mean ± SD 121 ± 181 112 ± 94 101 ± 68 107 ± 92
Prior HBV medication,c n (%) 9 (5) 5 (3) 11 (6) 8 (4)
Entecavir 5 (3) 3 (2) 4 (2) 2 (1)
Lamivudine 4 (2) 3 (2) 7 (4) 5 (3)
Clevudine 2 (1) 0 0 0
Telbivudine 0 1 (0$5) 2 (1) 2 (1)
aBlack or African American.
bFive patients with mixed genotypes were randomized: 1 genotype B/C; 3 genotypes D/G, and 1 genotype A/D.
cMultiple responses possible.
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R(P < .05) (Table 2). Groups A and B had similar rates of
HBeAg loss and anti-HBe seroconversion at weeks 48 and
72. At week seventy-two, 5, 7, and 6 patients in groups A, B,
and C, respectively, who had been retreated after stopping
therapy at week 48 achieved HBeAg loss.
At week 48, suppression of HBV DNA to <15 IU/mL was
achieved by 61%71% of patients in all treatment groups
that included TDF, compared with 21% of patients receiving
peginterferon alone. HBV DNA frequently rebounded after
week 48 in the absence of therapy (Table 2; Supplementary
Table 8). At week 72, the proportion of patients with
normalized ALT levels in group C (TDF monotherapy) was
73% as compared with 36%37% of patients in the
peginterferon-containing treatment groups (P < .0001). At
week 72, rates of sustained response in patients who had
stopped therapy and were not retreated were 23%, 22%,
and 19% in groups A, B, and D, respectively; P > .05.
Of the 555 patients randomized to the groups with
treatment ending at week forty-eight, 312 met the criteria
for TDF retreatment: 100 patients (54%) from group A; 100patients (54%) from group B, and 112 patients (61%) from
group D. The reasons for retreatment are shown in
Supplementary Table 9. None of the patients requiring TDF
retreatment after week 48 achieved HBsAg loss at week 72.
By week 72, viral resistance testing had been conducted
in 31 patients (4.3%) according to the protocol. Of these, 11
(35.5%) had no sequence changes in HBV polymerase/
reverse transcriptase compared with baseline, 11 (35.5%)
had unique polymorphic site changes, and 9 (29.0%) were
unable to be genotyped because of low viral load (HBV DNA
<172 IU/mL). No conserved site changes were observed in
patients while receiving a TDF-containing regimen.
Study drug discontinuation due to adverse events
occurred more frequently with peginterferon monotherapy
(8%) than in the other groups (04%) (Table 4). The most
common adverse events were headache, alopecia, pyrexia,
and fatigue/malaise, which are all characteristic of pegin-
terferon treatment. With the exception of fatigue/malaise,
which was more frequently recorded in group A, most
adverse events occurred at a similar frequency among the
Figure 1. Effect of TDF
and peginterferon as
combination or mono-
therapy on HBsAg loss.
The rate of HBsAg loss in
group A was signiﬁcantly
higher than rates for
groups C (P < .001) or D
(P¼.003), as well as group
B (unadjusted P < .001).
The rate of HBsAg loss in
group B did not signiﬁ-
cantly differ from that of
groups C (P ¼ .466) or
group D (P ¼ .883).
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ity of serious adverse events were patients who experienced
an increase in serum transaminases. These events occurred
at a similar frequency in patients receiving combination
therapy or peginterferon monotherapy, and were lowest in
patients receiving TDF monotherapy (15, 15, 2, and 18
events for groups AD, respectively).
After discontinuation of therapy at week 48 in groups
A, B, and D, a similar proportion of patients receiving
combination treatment and peginterferon monotherapy
experienced ALT elevations >400 U/L (males) or >300
U/L (females). These transaminase elevations decreased
with TDF retreatment. One patient in group B developed
mild hepatic encephalopathy during a hepatic ﬂare while
not receiving treatment; symptoms resolved after initiation
of TDF retreatment. One patient in group D decompensated
after week 72 (more details in the Supplementary
Material).Discussion
In this study in HBeAg-positive and HBeAg-negative CHB
patients without advanced liver disease, the rate of HBsAg
loss at week 72 was signiﬁcantly higher in patients receiving
TDF plus peginterferon for 48 weeks than in those receiving
monotherapy with either TDF or peginterferon. Patients
receiving combination therapy with a shorter course of
peginterferon (16 weeks) had a smaller decline in HBsAg
levels and a lower rate of HBsAg loss than patients receiving
48 weeks of peginterferon plus TDF (post-hoc analysis,
unadjusted). This study provides direct evidence that
combining 2 agents with different mechanisms of action for
a ﬁnite treatment duration can result in rates of serum
HBsAg loss signiﬁcantly higher than those obtained with
current standard-of-care monotherapy regimens.
The mechanism of action by which the TDF and pegin-
terferon combination induces HBsAg loss is not well un-
derstood. Active HBV replication can blunt the host immune
response by disrupting various intracellular pathways,
including those involved in antigen presentation andinterferon-dependent signaling.20 By rapidly reducing viral
replication and serum viral protein levels, including HBsAg,
TDF may improve responsiveness of the immune system to
immune modulators, such as interferon.21–23 The
on-treatment ALT elevations observed during this trial,
which were predictive of HBsAg loss appear to lend support
to the importance of an immune modulator in eliciting the
host response required for control of infection and HBsAg
loss. This is also supported by the signiﬁcantly lower rate of
response in group B, which included only 16 weeks of
peginterferon (included to explore whether limiting the
duration of peginterferon affected rates of HBsAg loss). As
would be expected, the level of HBsAg decline in group B
was similar to that in group A until peginterferon was dis-
continued; however, upon discontinuation of peginterferon
at week 16, HBsAg levels plateaued in group B so that few
patients had achieved HBsAg loss at week 48. These data
suggest that a peginterferon-sparing strategy is not sufﬁ-
cient to result in sustained immune control in most patients
with hepatitis B. There was one case of hepatic encepha-
lopathy and one case of ascites in patients who had received
a short course of peginterferon. As there is a risk of liver
decompensation in patents stopping peginterferon treat-
ment, it is important that patients are screened carefully for
underlying advanced ﬁbrosis before considering such a
treatment strategy.1
Although earlier trials combining lamivudine with
peginterferon did not improve HBsAg loss rates over those
observed with peginterferon alone,11,12,24 subsequent
studies have suggested that combination therapy may
induce greater HBsAg decline, possibly improving rates of
HBsAg loss.16,25,26 However, these studies were limited by
short duration, small sample size, and lack of control arms,
as well as poor tolerability of the regimens studied.27 Our
study is the ﬁrst to provide deﬁnitive evidence that patients
receiving a potent oral agent, with high barrier to resistance,
in combination with peginterferon can achieve higher rates
of HBsAg loss than those receiving monotherapy, with no
increase in adverse events compared with peginterferon
alone.
Table 2.Efﬁcacy Results at Weeks 48 and 72
Response
Group A (n ¼ 186)
TDF þ peginterferon
for 48 wk
Group B (n ¼ 184)
TDF þ peginterferon
for 16 weeks, TDF
for 32 wk
Group C (n ¼ 185)
TDF for 120 wk
Group D (n ¼ 185)
peginterferon for
48 wk
HBsAg loss
KaplanMeier estimate, %
Wk 48 7.3 2.8 0 2.8
Wk 72 9.1 2.8 0 2.8
P values for wk 72
vs group C <.001 NS
vs group D .003 NS
Markov 2-state estimate, %
Wk 48 7.3 2.3
Wk 72 6.8 1.1 0 2.8
P values for wk 72 0 2.8
vs group C <.001 NS
vs group D NS NS
HBsAg seroconversion
KaplanMeier estimate, %
Wk 48 5.7 0.6 0 2.3
Wk 72 8.1 0.6 0 2.9
HBsAg change from baseline,
log10 IU/mL
a
Wk 48 1.1 0.5 0.3 -0.8
Wk 72 1.3 0.3 0.4 -0.6
P values at wk 72
vs group C <.05 NS
vs group D <.05 NS
HBeAg loss, n/N (%)b
Wk 48 28/108 (25.9) 21/105 (20.0) 9/109 (8.3) 14/106 (13.5)
Wk 72 32/108 (29.6) 26/105 (24.8) 16/109 (14.7) 27/106 (25.5)
P values at wk 72
vs group C .009 NS
vs group D NS NS
HBeAg seroconversion, n/N (%)b
Wk 48 25/108 (23.1) 20/105 (19.0) 9/109 (8.3) 13/106 (12.3)
Wk 72 27/108 (25.0) 25/105 (23.8) 14/109 (12.8) 26/106 (24.5)
P values at wk 72
vs group C .025 .051
vs group D NS NS
HBV DNA <15 IU/mL, n/N (%)c
Wk 48 128/186 (68.8) 131/184 (71.2) 112/185 (60.5) 39/183 (21.3)
Wk 72 17/186 (9.1) 12/184 (6.5) 133/185 (71.9) 17/185 (9.2)
P values at wk 72
vs group C <.001 <.001
vs group D NS NS
ALT normalization – n/N (%)c
Wk 48 70/172 (40.7) 118/172 (68.6) 111/176 (63.1) 53/173 (30.6)
Wk 72 63/172 (36.6) 62/172 (36.1) 128/176 (72.7) 64/173 (37.0)
Sustained response (HBV DNA
<2000 IU/mL and ALT
normalization), n/N (%)c
Week 72 40/172 (23.3) 37/172 (21.5) NA 32/173 (18.5)
NA, not applicable.
aMissing data at analyzed time point or data from all time points after the start of TDF retreatment were excluded from analysis.
bPatients with missing data at the analyzed time point were considered nonresponders at that analyzed end point.
cPatients with missing data at the analyzed time point or patients who started on TDF retreatment were considered non-
responders at that analyzed end point.
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Table 3.Cumulative Hepatitis B Surface Antigen Loss Up To Week 72 According To Hepatitis B e Antigen Status and
Genotype
Group A (n ¼ 186)
TDF þ peginterferon
for 48 wk
Group B (n ¼ 184)
TDF þ peginterferon for
16 weeks, then TDF for 32 wk
Group C (n ¼ 185)
TDF for 120 wk
Group D (n ¼ 185)
Peginterferon
for 48 wk
Wk 48 Wk 72 Wk 48 Wk 72 Wk 48 Wk 72 Wk 48 Wk 72
HBeAg-positive (n ¼ 428), n/N (%)
Overall 7/108 (6.5) 10/108 (9.3) 3/105 (2.9) 4/105 (3.8) 0/109 0/109 4/106 (3.8) 4/106 (3.8)
Genotype A 2/8 (25.0) 3/8 (37.5) 1/8 (12.5) 2/8 (25.0) 0/6 0/6 0/5 0/5
Genotype B 2/27 (7.4) 3/27 (11.1) 1/26 (3.8) 1/26 (3.8) 0/25 0/25 2/26 (7.7) 2/26 (7.7)
Genotype C 2/57 (3.5) 3/57 (5.3) 0/57 0/57 0/59 0/59 1/58 (1.7) 1/58 (1.7)
Genotype D 1/15 (6.7) 1/15 (6.7) 1/13 (7.7) 1/13 (7.7) 0/17 0/17 1/16 (6.3) 1/16 (6.3)
Genotypes EH 0/1 0/1 0/1 0/1 0/2 0/2 0/1 0/1
HBeAg-negative (n ¼ 312), n/N (%)
Overall 4/78 (5.1) 6/78 (5.1) 1/79 (1.3) 1/79 (1.3) 0/76 0/76 1/79 (1.3) 1/79 (1.3)
Genotype A 2/9 (22.2) 3/9 (33.3) 0/8 0/8 0/8 0/8 0/9 0/9
Genotype B 1/23 (4.3) 2/23 (8.7) 1/25 (4.0) 1/25 (4.0) 0/24 0/24 1/27 (3.7) 1/27 (3.7)
Genotype C 1/21 (4.8) 1/21 (4.8) 0/22 0/22 0/19 0/19 0/21 0/21
Genotype D 0/24 0/24 0/23 0/23 0/24 0/24 0/22 0/22
Genotypes EH 0/1 0/1 0/1 0/1 0/1 0/1 0/0 0/0
NOTE. Overall, 7 patients seroreverted on or after wk 48; 5 HBeAg-positive patients (3 in group A: 2 genotype A patients and 1
genotype B patient, and 2 in group B: genotype A) and 2 HBeAg-negative patients (1 in group A: genotype B; 1 in group B:
genotype B).
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nation therapy, unlike peginterferon or TDF mono-
therapies, can induce HBsAg loss at a similar frequency in
both HBeAg-positive and HBeAg-negative patients and
across all major genotypes. However, response is not
entirely uniform and most patients do not achieve sus-
tained immune control. Patients with certain baseline
characteristics (eg, genotype A, HBeAg-positive status)
tend to have higher rates of HBsAg loss. These results are
consistent with previous studies of peginterferon mono-
therapy, where highest rates of HBsAg loss were achieved
in genotype A patients28 and in patients with higher ALTlevels.29,30 Indeed, the differences between baseline char-
acteristics in the current study and the phase 3 peginter-
feron studies11,12 could explain the slightly lower rate of
HBsAg loss in this study than observed with peginterferon
previously. For instance, more patients with lower ALT
levels than the phase 3 peginterferon studies, a factor that
has been associated with lower response rates to inter-
feron.1 Further work is needed to identify subgroups of
patients who might beneﬁt most from combination ther-
apy, and to determine optimal duration of therapy that
would minimize post-treatment HBsAg seroreversion. Five
of the 7 patients receiving combination therapy whoFigure 2.On-treatment
HBsAg decline from base-
line to week 48. Data
shown are mean ± 95%
CIs. Group A vs group B,
P < .001; group A vs
group C, P< .001; group A
vs D, P ¼ .016.
Table 4.Treatment Discontinuations and Adverse Events
Variable
Group A (n ¼ 186)
TDF þ peginterferon for 48 wk
Group B (n ¼ 184)
TDF þ peginterferon for 16 wk,
then TDF for 32 wk
Group C (n ¼185)
TDF for 120 wk
Group D (n ¼ 185) peginterferon
for 48 wk
All time points
without TDF
retreatment
(n ¼ 186)
All time points
on TDF
retreatment
(n ¼ 100)
All time points
without TDF
retreatment
(n ¼ 184)
All time points
on TDF
retreatment
(n ¼ 100)
Continued TDF
treatment (n ¼ 185)
All time points
without TDF
retreatment
(n ¼ 185)
All time points
on TDF
retreatment
(n ¼ 112)
Any nonserious adverse event, no. of
patients (%)a
145 (78) 17 (17) 138 (75) 21 (21) 81 (44) 150 (81) 25 (22)
Any serious adverse event, no. of
patients (%)
21 (11) 7 (7) 18 (10) 3 (3) 12 (7) 18 (10) 5 (5)
Discontinuation of treatment due to
adverse events, n (%)
8 (4) 1 4 (2) 1 (1) 0 (0) 14 (8) 0
Common adverse events, no. of patients
(%)b
Headache 54 (29) 3 (3) 37 (20) 2 (2) 16 (9) 52 (28) 2 (2)
Alopecia 46 (25) 0 32 (17) 0 1 (1) 45 (24) 0
Pyrexia 39 (21) 1 (1) 36 (20) 0 7 (4) 43 (23) 2 (2)
Fatigue 40 (22) 1 (1) 33 (18) 4 (4) 20 (11) 41 (22) 5 (5)
Decreased appetite 23 (12) 0 36 (20) 2 (2) 2 (1) 18 (10) 0
Myalgia 29 (16) 0 36 (20) 1 (1) 2 (1) 36 (20 1 (1)
Nausea@ 26 (14) 0 24 (13) 3 (3) 10 (5) 13 (7) 6 (5)
Pruritus 15 (8) 0 14 (8) 2 (2) 4 (2) 22 (12) 0
Asthenia 20 (11) 0 9 (5) 1 (1) 3 (2) 12 (7) 0
Malaise@ 20 (11) 0 12 (7) 0 2 (1) 7 (4) 2 (2)
Dizziness 20 (11) 0 18 (10) 0 9 (5) 17 (9) 4 (4)
Rash 20 (11) 1 (1) 17 (9) 1 (1) 1 (1) 9 (5) 2 (2)
Diarrhea 13 (7) 0 10 (5) 0 9 (5) 19 (10) 4 (4)
Inﬂuenza-like illness 19 (10) 0 17 (9) 0 10 (5) 16 (9) 2 (2)
Insomnia 19 (10) 0 14 (8) 0 6 (3) 18 (10) 1 (1)
Psychiatric disordersc 14 (8) 0 3 (2) 0 2 (1) 9 (5) 3 (3)
Anxiety 8 (4) 0 2 (1) 0 0 7 (4) 1 (1)
Nasopharyngitis 5 (3) 4 (4) 16 (9) 2 (2) 18 (10) 6 (3) 1 (1)
Grade 3/4 laboratory abnormalities, no.
of patients (%)
Anemia 8 (4) 0 3 (2) 0 2 (1) 4 (2) 1 (1)
Lymphopenia 12 (6) 1 (1) 7 (4) 0 7 (4) 11 (6) 1 (1)
Neutropenia 30 (16) 0 21 (11) 2 (2) 2 (1) 27 (15) 1 (1)
Thrombocytopenia 3 (2) 0 4 (2) 0 0 10 (5) 0
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LIVERexperienced HBsAg seroreversion after HBsAg loss had
achieved HBsAg loss at the end or shortly after the end of
their treatment and all seroconversions occurred within 3
months after the end of treatment. This suggests a possible
need for extension of therapy in this group of responders
to ensure durable HBsAg loss. The clinical relevance of
these results is still to be established. The increased rate of
HBsAg loss with combination therapy vs monotherapy is
encouraging, especially in genotype A patients, but it is
currently unclear whether the magnitude of this increase
will be sufﬁcient to change clinical practice. There is also
the need to understand more about the most effective way
of combining therapy. An alternative strategy, where
peginterferon is added to oral antiviral therapy in virally
suppressed patients has also demonstrated increased rates
of HBsAg loss, which is sustained 24 weeks after stopping
therapy, compared with oral antiviral therapy alone.31
However, the lack of a peginterferon monotherapy treat-
ment arm in this peginterferon add-on study by Bourliere
and colleagues31 means that it is not possible to conclude
that this effect is greater than would be achieved without
the oral agent.
Despite the fact that the observed rate of HBsAg loss in
the study was lower than that assumed in the study design,
reducing the power for comparison between groups A and
D, statistical signiﬁcance was still demonstrated between
groups A and D. We do not believe the lack of power affects
the interpretation of results. Because this study did not
include patients with cirrhosis or bridging ﬁbrosis, the
extrapolation of results to these patients is not possible.
Similarly, as only a small number of patients had been
previously treated with nucleoside analogs (n ¼ 33), there
were insufﬁcient data to assess the inﬂuence of prior HBV
therapy on treatment outcomes. In addition, unlike previ-
ous studies, our study permitted TDF retreatment for
patients who met certain criteria, such as increased HBV
replication and serum ALT elevation. It is unclear if this
management may have affected HBsAg decline and loss in
this subpopulation. It is also important to note that this
was an open-label, rather than a double-blind study.
Finally, prolonged follow-up of patients who had not
restarted TDF treatment would be required to determine
the long-term beneﬁts of response and durability of
outcome.
In conclusion, combination therapy with TDF plus
peginterferon for 48 weeks resulted in higher rates of
HBsAg loss than either monotherapy. This provides sup-
port to the concept of combination therapy of ﬁnite dura-
tion for patients with CHB. Further studies are required to
identify the optimal combination therapy regimen that
would allow more patients to achieve and sustain HBsAg
loss.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2015.09.043.
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Criteria for Retreatment
Patients in Groups A, B, or D who had stopped treatment
at week 48 were monitored every 2 weeks for the ﬁrst 12
weeks off therapy and then every 4 weeks for the subse-
quent 4 weeks to determine if they required prompt ﬂare
management by initiating/restarting TDF monotherapy.
Patients initiated/restarted TDF if they met one of the
following criteria:
 Increase of total bilirubin by >1.5 mg/dL (>25 mmol/L)
from study baseline andconcurrent ALT >30 U/L for
males and >19 U/L for females
 Increase in International Normalized Ratio (INR) >0.5
from study baseline or elevated INR 1.7, whichever is
lowest, in subjects with adequate vitamin K therapy and
concurrent ALT >30 U/L for males and >19 U/L for
females
 Lactate levels greater than upper limit of normal (ULN)
that were not a result of obvious nonhepatic etiology
 ALT >400 U/L in males or >300 U/L in females with or
without associated symptoms
 Any ALT elevation associated with change in other
laboratory parameters suggestive of worsening hepatic
function
 HBV DNA >5865 IU/mL (2000 copies/mL) assessed at
24 weeks’ off-treatment (irrespective of ALT level)
 Clinical or laboratory manifestations of hepatic
decompensation
 In males, ALT >60 IU/L and 150 IU/L and in females
ALT >38 U/L and 95 U/L persisting for 84 days and
HBV DNA 15 IU/mL
 ALT >150 IU/L and 400 IU/L (male) or ALT >95 U/L
and 300 U/L (female) persisting for 28 days
Patients requiring TDF retreatment continued treatment
until week 120.
Patients with persistently elevated ALT levels with >60
U/L for males (but <400 U/L) or >38 U/L for females (but
<300 U/L) with HBV DNA 15 IU/mL were followed up at
least every 2 weeks until meeting a criterion for TDF rein-
itiation or until ALT returned to normal levels.
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Randomization and Masking
Randomization was stratiﬁed by screening HBeAg status
and HBV genotype, forming a total of 10 strata as shown in
Supplementary Table 1. Subjects were allocated into 1 of the
4 treatment arms in the 1:1:1:1 ratio.
Eligibility Criteria
Inclusion Criteria
All patients had to meet the following inclusion criteria:
 Adult subjects (aged 1875 years) with documented
CHB (eg, positive for either serum HBsAg or HBV DNA
for at least 6 months) before baseline
 Anti-HBV treatment-naïve subjects and subjects who
have taken oral anti-HBV nucleoside therapy (lam-
ivudine, telbivudine, clevudine, or entecavir) with the
last dose at least 24 weeks before screening
 HBeAg-positive or HBeAg-negative
 HBV DNA 20,000 IU/mL for HBeAg-positive patients
and HBV DNA 2000 IU/ml for HBeAg-negative
patients
 ALT >54 U/L and 400 U/L for men and >36 U/L and
300 U/L for women
 Creatinine clearance (CLcr) 70 mL/min, as calculated
by the CockcroftGault equation (performed by the
central laboratory)
Exclusion Criteria
Subjects who meet any of the following exclusion criteria
were excluded from the study:
 Evidence of bridging ﬁbrosis or cirrhosis at screening as
conﬁrmed by liver biopsy within 12 months before ﬁrst
visit. In countries where FibroScan is approved for
clinical use, FibroScan (<8 kPa) could be used to verify
the absence of bridging ﬁbrosis and cirrhosis. Patients
with FibroScan >8 kPa were excluded unless a biopsy
within the 12 months before ﬁrst visit conﬁrmed the
absence of bridging ﬁbrosis and cirrhosis
 Evidence of decompensated liver disease deﬁned as
direct (conjugated) bilirubin >1.2  ULN, prothrombin
time >1.2 ULN, serum albumin <3.5 g/dL or history
of clinical hepatic decompensation (eg, ascites, jaundice,
encephalopathy, variceal hemorrhage). Patients with an
isolated increase in direct bilirubin >6.1 mmol/L but
<10.2 mmol/L, in the presence of a platelet count
>100,000/mm3 and normal INR may qualify for the
trial
 Absolute neutrophil count <1500/mm3, platelet
<100,000/mm3, hemoglobin <10 g/dL for female
subjects or <11 g/dL for male subjects
 Evidence of hepatocellular carcinoma
 History of severe depression or known severe psychi-
atric disease
 History of signiﬁcant renal disease (eg, nephrotic syn-
drome, renal dysgenesis, polycystic kidney disease,
congenital nephrosis, acute tubular necrosis, other renal
disease)
 Thyroid dysfunction
 History of autoimmune disease (eg, lupus, rheumatoid
arthritis, autoimmune thyroiditis)
 Signiﬁcant bone disease (eg, osteomalacia, chronic
osteomyelitis, osteogenesis imperfecta, osteo-
chrondroses, history of multiple bone fractures)
 Pregnant. A negative serum pregnancy test was
required for female subjects of childbearing potential
and all sexually active female subjects of childbearing
potential had to agree to use a protocol-recommended
method of contraception during heterosexual inter-
course throughout the study and for 30 days after the
last dose of study medication. Lactating female patients
had to agree to discontinue nursing before initiation of
the study
 Previous treatment with any form of interferons and
anti-HBV nucleotides (TDF or adefovir dipivoxil)
 Co-infection with human immunodeﬁciency virus, hep-
atitis C virus, or hepatitis delta virus
 Ongoing therapy with any of the following: nephro-
toxic agents; parenteral aminoglycoside antibiotics
(eg, gentamicin, tobramycin, amikacin); cidofovir;
cisplatin; foscarnet; intravenous amphotericin B;
intravenous pentamidine; oral or intravenous ganci-
clovir; ciclosporin; tacrolimus; intravenous vancomy-
cin; chronic daily nonsteroidal anti-inﬂammatory drug
therapy; hepatotoxic agents (eg, anabolic steroids,
isoniazid, itraconazole, ketoconazole, rifabutin,
rifampin, and other agents with signiﬁcant hepatotoxic
potential); competitors of renal excretion (eg, pro-
benecid); systemic chemotherapeutic agents; systemic
corticosteroids; interleukin-2; and other immunomo-
dulating agents and investigational agents (unless
approved by the sponsor). Administration of any of
these medications had to be discontinued at least 30
days before the baseline visit and for the duration of
the study period
 Known hypersensitivity to the study investigational
medicinal product, metabolites, or formulation
excipients
 Any other condition (including alcohol or substance
abuse) or prior therapy that, in the opinion of the
investigator, would make the subject unsuitable for
the study or unable to comply with dosing
requirements
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Study Visit Schedule
Study visits occurred every 4 weeks between week 4
and week 16 of treatment and then every 8 weeks from
week 24 to week 48. After week 48, visits occurred every 2
weeks up to week 60, every 4 weeks up to week 72 and 12
weeks up to week 120. The assessments at each visit are
shown in Supplementary Table 1.
Assessment of Adverse Events
All adverse events were assessed and recorded by the
investigator as described in the protocol. A serious adverse
event was deﬁned as any adverse drug experience that
resulted in death, a life-threatening situation, hospitalization
or prolongation of existing hospitalization, persistent or
signiﬁcant disability/incapacity. Further details are pro-
vided in the protocol. In addition, speciﬁc to this study, the
following had to be reported as a serious adverse event:
 Serum ALT >2  baseline levels and >400 U/L (male)
or 300 U/L (female), with or without associated
symptoms
 Conﬁrmed ALT elevation (deﬁned as 1-grade shift or
2  previous value) associated with conﬁrmed changes
outside of the normal range in other laboratory
parameters suggestive of worsening hepatic function
(total bilirubin 2 mg/dL above baseline, INR 0.5
over baseline or elevated INR 1.7, whichever is lowest,
abnormal serum albumin 1 g/dL below baseline or
elevated serum lactate levels (if available), deﬁned as
>2 ULN per the Adult AIDS Clinical Trials Group
guidelines
 Any clinical manifestations of hepatic decompensation
(variceal bleeding, hepatic encephalopathy, or ascites
requiring diuretics or paracentesis)
Resistance Monitoring
Serum samples collected at each time point were stored
for drug-resistance monitoring. Genotypic analyses were
conducted by population sequencing at DDL Diagnostic
Laboratories (Rijswijk, The Netherlands). Population
sequencing of the HBV polymerase/reverse transcriptase
(amino acids 1344) was attempted for any patient on a
TDF-containing regimen for at least 24 weeks who met the
following criteria: HBV DNA 117 IU/mL at week 48
(groups A and B) or week 72 (group C) or their last visit on
treatment before discontinuation. This includes patients
that may have experienced a virologic blip or breakthrough
at weeks 48 or week 72, or their last visit on treatment.
Virologic blips or breakthroughs were deﬁned as 1 or 2
visits, respectively, with HBV DNA 117 IU/mL after having
HBV DNA <117 IU/mL or a 1 log10 or greater increase in
HBV DNA from nadir.
Methodology for sequence analysis as well and the
deﬁnition of conserved/polymorphic site changes have been
summarized previously.1
Additional Statistical Methods
The study had 4 prespeciﬁed hypotheses, divided into 2
families. The ﬁrst family consisted of 2 hypotheses to eval-
uate the full course of TDF plus peginterferon for 48 weeks
against 2 monotherapies: groups A vs group C and group D.
The second family consisted of 2 hypotheses to evaluate the
shorter course of TDF plus peginterferon for 16 weeks fol-
lowed by 32 weeks of TDF alone against 2 monotherapies:
group B vs groups C and D.
pA,B,C,D denoted the probability of HBsAg loss in groups
A, B, C, and D, respectively. The ﬁrst family consisted of 2
hypotheses:
H110 : pA  pC H111 : pA>pC
H120 : pA  pD H121 : pA>pD
The second family consisted of 2 hypotheses:
H210 : pB  pC H211 : pB>pC
H220 : pB  pD H221 : pB>pD
Each family was tested using a Holm separable multiple
testing procedure with truncation fraction g ¼ 0.5. The
details are as follows:
1. In family 1, let P11 and P12 be the P-values corre-
sponding to hypotheses H110 and H120. Order the P
values from smallest to largest and denote them P(11)
 P(12) and the corresponding hypotheses H(110) and
H(120), respectively. Test these hypotheses using the
Holm procedure at an a ¼ 0.05.
a. If P(11) > a/2, then fail to reject H(110) and all
testing stops.
b. If P(11)  a/2, then reject H(110).
i. If P(12) > 3a/4, then fail to reject H(120). Go to
family 2
ii. If P(12)  3a/4, then reject H(120). Go to
family 2.
2. In family 2, let P21 and P22 be the P-values corre-
sponding to hypotheses H210 and H220. Order the P
values from smallest to largest and denote them P(21)
 P(22) and the corresponding hypotheses H(210) and
H(220), respectively. Test these hypotheses using the
Holm procedure at an a ¼ a2.
a. If P(21) > a2/2, then fail to reject H(210) and all
testing stops.
b. If P(11)  a2/2, then reject H(210).
i. If P(12) > a2, then fail to reject H(220).
ii. If P(12)  a2, then reject H(220).
If both hypotheses in family 1 are rejected, then a2 ¼ 0.05. If
only one hypothesis is rejected in family 1, then a2 ¼ a –
[g þ (1-g)*(1/2)] a ¼ a – (3/4) a ¼ (1/4) a ¼ 0.0125.
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Additional Safety Details
A 51-year-old Asian female, randomized to group B, was
documented as having a decompensating liver event shortly
after week 72, while on drug-free follow-up. At the time of
the decompensating event, the patient had ALT <5 ULN
with central laboratory INR of 1.37. She was started on
diuretics for management of ascites. The patient qualiﬁed
for inclusion in the study as the screening liver biopsy
showed stage 0 ﬁbrosis. There was evidence of more
advanced liver disease: a baseline computed tomography
scan showed changes consistent with liver cirrhosis, a
baseline esophagogastroduodenoscopy revealed evidence of
esophageal varices with baseline laboratory showing
platelet of 100/mm3. A computed tomography scan con-
ducted in week 40 indicated changes consistent with
cirrhosis with splenomegaly: esophageal/paraesophageal/
gastric varices and ascites.
Reference
1. Kitrinos KM, Corsa A, Liu Y, et al. No detectable resis-
tance to tenofovir disoproxil fumarate after 6 years of
therapy in patients with chronic hepatitis B. Hepatology
2014;59:434–442.
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Supplementary Table 2.Study Procedures
Procedures
Screening
Up to 15 d
Baseline
d 1
Every 4 wk
wk 4, 8, 12, 16
±2 d
Every 8 wk
wk 24, 32, 40, 48
±3 d
Every 2 wk
wk 50, 52, 54,
56, 58, 60
±2 d
Every 4 wk
wk 64, 68, 72
±3 d
Every 12 wk
Early
discontinuation
wk 84
±3 d
wk 96
±3 d
wk 108
±3 d
wk 120
±3 d
Written informed consent X
Medical HBV history,
treatment history
X X
Vital signs, height, weight,
physical examination
X X X X X X X X X X X
HIV, HCV, HDV, HBV DNA
genotyping
X
a-Fetoprotein X X (wk 24, 48) X (wk72) X (wk 96) X (wk 120)
TSH X X (wk 12) X (wk 24, 32, 48)
Hepatic ultrasound or
computed tomography
X
Biopsy or FibroScan X
HBV DNA quantiﬁcation and
HBsAg quantiﬁcation
X X X X X X X X X X X
HCV, hepatitis C virus; HDV, hepatitis D virus; HIV, human immunodeﬁciency virus; TSH, thyroid-stimulating hormone.
January
2016
TDF
+
Peginterferon
Com
bination
Therapy
in
CHB
144.e5
Supplementary Table 3.Reasons for Screening Failures
Inclusion criterion
failed or exclusion
criterion met Description No. of patientsa
Inclusion criterion 1 Adult aged 1875 y with chronic hepatitis B (positive serum HBsAg 6 mo) 32
Inclusion criterion 2 Anti-HBV treatment-naïve subjects. Subjects who have taken <12 wk of oral anti-HBV
nucleoside therapy with the last dose 24 wk before screening are also eligible
4
Inclusion criterion 3 Positive or negative for HBeAg 6
Inclusion criterion 4 HBV DNA 105 copies/mL for HBeAg-negative patients and 106 copies/mL for HBeAg-
positive patients
Amendment 4: HBV DNA 20,000 IU/mL
Amendment 5: HBV DNA 20,000 IU/mL for HBeAg-positive and 2000 IU/mL for HBeAg-
negative
252
Inclusion criterion 5 ALT >2 ULN and 10 ULN
Amendment 2: ALT >60 U/L and 400 U/L for men and >40 U/L and 300 U/L for women
Amendment 4: ALT >54 U/L and 400 U/L for men and >36 U/L and 300 U/L for women
493
Inclusion criterion 6 CLcr 70 mL/min, as calculated by the Cockcroft-Gault equation
Amendment 2: CLcr 80 mL/min
Amendment 4: CLcr 70 mL/min
79
Inclusion criterion 7 A negative serum pregnancy test is required for female subjects of childbearing potential 2
Inclusion criterion 8 All sexually active female subjects of childbearing potential must agree to use a protocol-
recommended method of contraception during heterosexual intercourse throughout the
study and for 30 d after the last dose of study medication
2
Inclusion criterion 9 Lactating female subjects must agree to discontinue nursing before initiation of study
investigational medicinal product
0
Exclusion criterion 1 Known cirrhosis according to clinical evaluation at study entry and conﬁrmation by recent
USSD/CT scan/Fibroscan and/or liver histology within 6 mo
Amendment 1: Evidence of bridging ﬁbrosis or cirrhosis
114
Exclusion criterion 2 Decompensated liver disease deﬁned as direct (conjugated) bilirubin >1.2 ULN,
prothrombin time >1.2 ULN, serum albumin <3.5 g/dL, or history of clinical hepatic
decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)
69
Exclusion criterion 3 Absolute neutrophil count <1500/mm3, platelet count <100,000/mm3, hemoglobin <10 g/dL
for female subjects or <11 g/dL for male subjects
42
Exclusion criterion 4 Evidence of hepatocellular carcinoma 2
Exclusion criterion 5 History of depression or known psychiatric disease
Amendment 2: History of severe depression or known severe psychiatric disease
1
Exclusion criterion 6 History of signiﬁcant renal disease (eg, nephrotic syndrome, renal dysgenesis, polycystic
kidney disease, congenital nephrosis, acute tubular necrosis, other renal disease)
0
Exclusion criterion 7 Thyroid dysfunction 19
Exclusion criterion 8 History of autoimmune disease (eg, lupus, rheumatoid arthritis, autoimmune thyroiditis) 2
Exclusion criterion 9 Signiﬁcant bone disease (eg, osteomalacia, chronic osteomyelitis, osteogenesis imperfecta,
osteochrondroses, history of multiple bone fractures)
0
Exclusion criterion 10 Pregnant 0
Exclusion criterion 11 Previous treatment with any form of interferons and anti-HBV nucleotides 4
Exclusion criterion 12 Co-infection with human immunodeﬁciency virus, hepatitis C virus or hepatitis delta virus 22
Exclusion criterion 13 Ongoing therapy with nephrotoxic agents, competitors of renal excretion, systemic
chemotherapeutic agents, systemic corticosteroids, interleukin-2 and other
immunomodulating agents, investigational agents
4
Exclusion criterion 14 Known hypersensitivity to the study investigational medicinal product, metabolites or
formulation excipients
0
Exclusion criterion 15 Any other condition (including alcohol or substance abuse) or prior therapy that, in the
opinion of the Investigator, would make the subject unsuitable for the study or unable to
comply with dosing requirements
3
CLcr, creatine clearance; CT, computed tomography.
aNote that some patients met more than one criterion.
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Supplementary Table 4.Adherencea to Treatment
Group A (n ¼ 186)
TDF þ peginterferon
for 48 wk
Group B (n ¼ 184)
TDF þ peginterferon
for 16 wk, then TDF
for 32 wk
Group C (n ¼ 185)
TDF for 120 wk
Group D (n ¼ 185)
peginterferon for 48 wk
Adherence to peginterferon,%, mean
± SD
98.5 ± 4.5 96.9 ± 10.5 NA 98.8 ± 3.6
80% adherence to peginterferon,
no. of patients (%)
184 (99.5) 177 (97.3) NA 181 (98.9)
Adherence to TDF, %, mean ± SD 98.5 ± 3.3 98.4 ± 4.3 98.6 ± 3.4 NA
80% adherence to TDF, no. of
patients (%)
182 (98.9) 182 (99.5) 183 (98.9) NA
NA, not applicable.
aAdherence to TDF was calculated as a ratio of the tablets taken over the tablets prescribed. Adherence to peginterferon was
calculated as a ratio of the syringes administered over the syringes prescribed.
Supplementary Table 5.Cumulative Hepatitis B Surface Antigen Loss by Hepatitis B e Antigen Status and Genotype at
Week 48
Cumulative HBsAg loss
up to wk 48
Group A (n ¼ 186)
TDF þ peginterferon
for 48 wk
Group B (n ¼ 184)
TDF þ peginterferon
for 16 wk, then TDF
for 32 wk
Group C (n ¼ 185)
TDF for 120 wk
Group D (n ¼ 185)
Peginterferon for 48 wk
HBeAg-positive (n ¼ 432)
Overall, n (%) 9/108 (8.3) 4/106 (3.8) 0/110 4/108 (3.7)
Genotype, n/N (%)
A 3/8 (37.5) 2/8 (25.0) 0/6 0/6
B 3/27 (11.1) 1/26 (3.8) 0/26 2/27 (7.4)
C 2/57 (3.5) 0/58 0/59 1/58 (1.7)
D 1/15 (6.7) 1/13 (7.7) 0/17 1/16 (6.3)
EH 0/1 0/1 0/2 0/1
HBeAg-negative (n ¼ 308)
Overall, n/N (%) 4/78 (7.8) 1/78 (1.3) 0/75 1/77 (1.3)
Genotype, n/N (%)
A 2/9 (22.2) 0/8 0/8 0/8
B 1/23 (4.3) 1/25 (4.0) 0/23 1/26 (3.8)
C 1/21 (4.8) 0/21 0/19 0/21
D 0/24 0/23 0/24 0/22
EH 0/1 0/1 0/1 0/0
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Supplementary Table 6.Cox Regression Analysis of Baseline Factors Associated With Hepatitis B Surface Antigen Loss
Comparison
No. of
observations Hazard ratio Lower limit Upper limit P value
Overall
P value
Univariate analysis
30 years vs <30 years 740 0.88 0.38 2.02 .761
Male vs female 740 1.72 0.69 4.28 .245
Non-Asian vs Asian 740 1.62 0.72 3.64 .240
Baseline body mass index 740 1.05 0.96 1.14 .295
Baseline weight, kg 740 1.01 0.99 1.03 .429
Baseline height, m 740 0.99 0.95 1.04 .755
Baseline HBeAg status
(positive vs negative)
740 0.6 0.26 1.38 .232
Genotype 740 .002
B vs A 0.34 0.14 0.86 .024
C vs A 0.11 0.04 0.33 <.001
D vs A 0.15 0.04 0.48 .004
C vs B 0.34 0.11 0.92 .049
D vs B 0.44 0.11 1.35 .202
D vs C 1.30 0.30 4.88 .714
ALT <ULN vs >ULN, U/L 740 0 0 .992
Baseline HBsAg, log10 IU/mL 740 1.04 0.65 1.66 .878
Baseline HBV DNA, log10 IU/mL 740 1.02 0.8 1.31 .859
Multivariate analysis
Genotype 625 .001
B vs A 0.11 0.03 0.38 <.001
C vs A 0.06 0.01 0.25 <.001
C vs B 0.57 0.12 2.36 .458
D vs A 0.13 0.02 0.54 .015
D vs B 1.13 0.18 5.67 .892
D vs C 1.97 0.32 10.53 .455
Supplementary Table 7.Cox Regression Analysis of On-Treatment Factors Associated With Hepatitis B Surface Antigen Loss
Comparison
No. of
observations
Hazard
ratio
Lower
limit
Upper
limit
P
value
Overall
P value
Univariate analysis
Treatment 740 .008
Group B vs group A 0.33 0.11 0.81 .029
Group C vs group A 0.03 0.00 0.22 .018
Group D vs group A 0.33 0.11 0.82 .030
Group C vs group B 0.09 0.00 0.79 .115
Group D vs group B 1.01 0.30 3.41 .989
HBsAb <10 IU/mL vs HBsAb >10 IU/mL at wk 12 708 0.28 0.09 1.38 .061
Change in HBsAg <1 log vs >1 log at wk 12 711 23.2 9.54 56.43 <.001
HBV DNA <15 IU/mL vs HBV DNA >15 IU/mL at wk 12 709 2.94 1.25 6.93 .014
HBsAg <2 log vs >2 log at wk 12 711 12.44 5.45 28.37 <.001
HBsAg <3 long vs >3 log at wk 12 711 7.11 3.01 16.76 <.001
ALT >400 U/L vs <400 U/L (males) or
> 300 U/L vs <400 U/L (females) in ﬁrst 12 wk
729 10.69 4.62 24.71 <.001
Multivariate analysis
Treatment 625 .029
Group B vs group A 0.27 0.08 0.80 .033
Group C vs group A 0.09 0.00 0.74 .097
Group C vs group B 0.32 0.00 3.34 .456
Group D vs group A 0.26 0.07 0.77 .032
Group D vs group B 0.96 0.22 4.10 .960
Group D vs Group C 3.00 0.26 414.79 .479
Decline in HBsAg >1 log vs <1 log at wk 12 625 7.8 2.05 29.22 .003
ALT ﬂare in ﬁrst 12 wk vs no ﬂare 625 4.65 1.54 14.46 .0009
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Supplementary Table 8.Proportion of Subjects With Hepatitis B Virus DNA <117 IU/mL (Protocol-Deﬁned Secondary
End Point)
HBV DNA <117 IU/mL
Group A (n ¼ 186)
TDF þ peginterferon
for 48 wk
Group B (n ¼ 184)
TDF þ peginterferon
for 16 wk, then TDF
for 32 wk
Group C (n ¼ 185)
TDF for 120 wk
Group D (n ¼ 185)
Peginterferon for 48 wk
Wk 48, no. of patients (%) 160 (86.0) 153 (83.2) 149 (80.5) 61 (33.0)
Wk 72, no. of patients (%) 22 (11.8) 19 (10.3) 157 (84.9) 15 (8.1)
Supplementary Table 9.Reasons for Retreatmenta
Retreatment criteria
Total no. of patients
meeting retreatment
criteria
Increase of total bilirubin by >1.5 mg/dL (>25 mmol/L) from study baseline and concurrent ALT
>30 U/L for males and >19 U/L for females
1
Increase in INR >0.5 from study baseline or elevated INR 1.7, whichever is lowest, in subjects
with adequate vitamin K therapy and concurrent ALT >30 U/L for males and >19 U/L for
females
0
Lactate levels >ULN that were not a result of obvious nonhepatic etiology 9
ALT >400 U/L in males or >300 U/L in females with or without associated symptoms 65
Any ALT elevation associated with change in other laboratory parameters suggestive of
worsening hepatic function
8
HBV DNA >5865 IU/mL (20,000 copies/mL) assessed at 24 wk off treatment (irrespective of ALT
level)
178
Clinical or laboratory manifestations of hepatic decompensation 0
In males, ALT >60 IU/L and 150 IU/L and in females ALT >38 U/L and 95 U/L persisting for
84 d and HBV DNA 15 IU/mL
37
ALT >150 IU/L and 400 IU/L (male) or ALT >95 U/L and 300 U/L (female) persisting for 28 d 27
Unknown 3
aNote that some patients met more than one criterion.
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Supplementary Figure 1. Patient disposition. *Eleven subjects were randomized but not dosed; 4 withdrew consent after
randomization and reasons are not provided for the remaining 7. †The analyzed population represents patients included in the
KaplanMeier estimate, the missing ¼ failure analysis and the safety analysis.
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